Using RU58841 and topical minoxidil together is fine and does not cancel out the benefits of each. Applying both treatments consecutively is acceptable.
The conversation is about finding a pure high molecular weight hyaluronic acid for the scalp after microneedling. A user suggests using a product from The Ordinary.
A 23-year-old male has been experiencing hair loss since 2022 and has used minoxidil and dutasteride with reduced shedding but no hair regrowth. He is considering PRP with mesotherapy and red light therapy, GFC, or exosomes, with a preference for exosomes due to efficiency and a reputable clinic.
Exploring the idea of transplanting miniaturized hair follicles to healthier areas to potentially reverse hair loss, with concerns about DHT sensitivity and scar tissue formation. The conversation also humorously considers using mice for hair growth experiments.
The conversation discusses the results of a group buy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The user experienced significant hair regrowth in three months using a capsule containing minoxidil and finasteride. They reported no major side effects and plan to continue the treatment until their late 20s.
The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.
The user is experiencing hair loss despite using finasteride and Rogaine, with conflicting diagnoses from different hospitals. One suggests no hair loss, while another recommends continuing medication; a suggestion to see a dermatologist for proper assessment is given.
The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.
The user has been using minoxidil and finasteride for hair loss without positive results and switched to dutasteride 1.5 months ago. They suspect seborrheic dermatitis might be affecting the effectiveness of these treatments.
New hair loss treatment called scube3 discussed with mixed opinions. Concerns about pharmaceutical companies preferring repetitive treatments over cures due to profit.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
The conversation is about microneedling for hair loss. The conclusion is that there are differing opinions on the depth and frequency of microneedling, with some studies suggesting positive results with 1.5mm depth once a week, while others prefer lower depths and less frequent sessions.
High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.
The conversation discusses hair loss treatments, specifically the use of dutasteride, finasteride, and the potential of mesotherapy. The user experiences hair loss despite low DHT levels and considers localized dutasteride treatment, while others suggest consulting a dermatologist and exploring other causes like malabsorption.
The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.
The conversation is about managing seborrheic dermatitis and hair loss using treatments like Nizoral, Kelual DS, KPL, and MCT oil daily. The user is concerned about the effectiveness and safety of using MCT oil every day.
The user has tried various hair loss treatments, including topilutamide, alfatradiol, pyrilutamide, and topical spironolactone, but experienced headaches. They are inquiring about the availability and legality of clascoterone in Spain.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
A user is seeking advice on how often to use a minoxidil solution with 0.025% tretinoin, considering using it every other evening instead of regular minoxidil twice a day. They are asking for experiences and opinions on this usage frequency.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.
User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
The conversation discusses using minoxidil with retinol for hair loss treatment. Users share their experiences and opinions on the effectiveness of this combination.